|1.||Guma, Monica: 2 articles (02/2013 - 05/2009)|
|2.||Karin, Michael: 2 articles (02/2013 - 05/2009)|
|3.||Yang, Peixin: 2 articles (02/2013 - 01/2008)|
|4.||Alcorn, John F: 2 articles (01/2012 - 04/2009)|
|5.||Janssen-Heininger, Yvonne M W: 2 articles (01/2012 - 04/2009)|
|6.||Davis, Roger J: 2 articles (06/2011 - 09/2006)|
|7.||Park, Kwon Moo: 2 articles (08/2008 - 01/2002)|
|8.||Chen, Zhihua: 1 article (01/2015)|
|9.||Rui, Yan-Ning: 1 article (01/2015)|
|10.||Zhang, Sheng: 1 article (01/2015)|
04/01/1998 - "In contrast, neither c-Jun N-terminal kinase 1 nor p42/p44MAPK activity was altered after ischemia. "
10/01/2011 - "Activation of c-Jun N-terminal kinase 1/2 regulated by nitric oxide is associated with neuronal survival in hippocampal neurons in a rat model of ischemia."
04/01/2001 - "Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes."
08/01/2008 - "In addition, WHW administration attenuated the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase 1/2 (JNK1/2) and attenuated the activation of nuclear factor-kappa B (NF-kappaB) in the kidneys subjected to ischemia. "
01/18/2002 - "Prior UO results in reduced postischemic phosphorylation of c-Jun N-terminal stress-activated protein kinase 1/2 (JNK1/2), p38, mitogen-activated protein kinase (MAPK) kinase 4 (MKK4), and MKK3/6. Very few cells stain positively for proliferating cell nuclear antigen after obstruction, indicating that subsequent protection against ischemia is not related to proliferation with increased numbers of newly formed daughter cells more resistant to injury. "
01/01/2008 - "It has been established that c-Jun N-terminal kinase 1 (JNK1) is essential to the pathogenesis of insulin resistance and type 2 diabetes. "
06/01/2009 - "JNK1 (c-Jun N-terminal kinase 1) plays a crucial role in the regulation of obesity-induced insulin resistance and is implicated in the pathology of Type 2 diabetes. "
08/15/2010 - "For instance, all morbidly obese patients, irrespective of their insulin resistance, showed increased expression of TNFalpha (tumour necrosis factor alpha) and activation of JNK1/2 (c-Jun N-terminal kinase 1/2). "
09/01/2009 - "c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists."
09/01/2011 - "Similarly, inhibition of JNK1 kinase by expression of dominant-negative JNK1 also resulted in improved hepatic insulin signaling, indicating that IKK and JNK1 kinases contribute to critical illness-induced insulin resistance in liver."
|3.||B-Cell Lymphoma (Lymphoma, B Cell)
12/20/2013 - "Myc suppression has an inhibitory effect on autophagy via reduction of c-Jun N-terminal kinase 1 (JNK1) and B-cell lymphoma 2 (Bcl2) phosphorylation. "
01/01/2013 - "Various molecular signals, such as B-cell lymphoma (Bcl)-2, Bcl-2-associated death promoter, Bcl-x, caspase-3, cleaved caspase-3, Fas, signal transducer and activator of transcription 5, extracellular signal-regulated kinases, MMP-9 and pan-janus kinase/stress-activated protein kinase 1, indicated that apoptosis, inhibition of growth and invasion was cleared on sorafenib-eluting PCL films. "
|4.||Critical Illness (Critically Ill)
|5.||Cardiomegaly (Heart Hypertrophy)
07/01/2014 - "Furthermore, analysis of the signaling events in vitro and in vivo revealed that CARD6-mediated protection against cardiac hypertrophy was attributed to the interruption of mitogen-activated protein kinase kinase (MEK) kinase-1-dependent MEK-extracellular signal-regulated protein kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase 1/2 (JNK1/2) activation. "
|2.||Protein Kinases (Protein Kinase)
|3.||Caspase 3 (Caspase-3)
|5.||Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
|6.||STAT5 Transcription Factor
|7.||Proliferating Cell Nuclear Antigen (PCNA)
|8.||sorafenib (BAY 43-9006)
|10.||Mitogen-Activated Protein Kinase 8